Abstract
Pemphigus vulgaris is an autoimmune mucocutaneous blistering disorder characterized by the presence of pathogenic autoantibodies against adhesion proteins on epidermal keratinocytes called desmogleins (DSG1 and DSG 3). It has a chronic relapsing and remitting course and in severe cases can be life threatening. Those patients who fail to respond to traditional treatments are considered to have refractory pemphigus. This review focuses on various therapies that are currently in practice as well as in pre-clinical or clinical trials for steroid-resistant pemphigus vulgaris.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
